Eurofins Scientific will help Adial validate a companion diagnostic for a drug being developed and identify patients for enrollment into a Phase III trial.
The addition of the Y chromosome detection will enable the firm to refine its already-approved MaternalFetalScreen T1 test to provide personalized risk assessment.
The acquisition of the Netherlands-based lab follows an acquisition of a Belgian clinical lab earlier this month.
LVP gives Eurofins an entry platform into the Belgian market, and generated about €5 million in revenues in 2017, the company said.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The company said it has acquired four clinical labs in France since the beginning of 2017. Together, the four labs have combined revenues of more than €10 million.
The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.